Procera AVH is not established as a treatment for memory loss or dementia. It is a dietary supplement marketed to support memory, focus, reaction time, and general cognitive function. Its ingredients have been studied, but the main Procera trial involved healthy adults—not people with dementia. The product also raises practical safety questions because its label hides individual doses and includes vinpocetine.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What does Procera AVH contain?
- What does the company claim?
- What did the Procera clinical study find?
- How strong is the broader evidence?
- What safety questions should readers ask?
What does Procera AVH contain?
The current Procera Health label lists a 1,515-mg proprietary blend containing acetyl-L-carnitine HCl, vinpocetine, and huperzine A. A proprietary blend gives the combined weight but not the amount of each ingredient. That omission matters when comparing the product with clinical research.
The published Procera study disclosed specific daily doses, but the current label does not show whether today's formula uses the same proportions. It also makes an individualized safety review harder. A reader or clinician cannot determine the dose of vinpocetine or huperzine A from the total blend amount alone.
What does the company claim?
procera Health markets AVH for "brain health and cognitive function." It says the supplement can support memory, focus, and reaction time. These are support claims, not proof that AVH treats diagnosed memory loss, mild cognitive impairment, or dementia.
A person may also perform differently on a cognitive test without experiencing a meaningful improvement in everyday functioning. Marketing language should therefore be read narrowly. "Supports memory" does not mean "reverses memory loss," prevents dementia, or replaces an evaluation of memory symptoms.
What did the Procera clinical study find?
The 2019 study in the International Journal of Neurology and Neurotherapy randomized 90 healthy adults aged 22 to 66. For 28 days, participants received placebo or daily doses of 1,500 mg acetyl-L-carnitine, 15 mg vinpocetine, and 150 micrograms of huperzine A. Cognitive data were available for 73 participants.
The active group improved more than the placebo group on a composite measure called "Quality of Memory." However, speed of memory and sustained attention showed no significant between-group benefits. The study excluded people with dementia and those taking anticoagulants. Its findings therefore cannot establish that Procera AVH treats clinical memory loss or is safe and effective for those excluded groups.
How strong is the broader evidence?
Evidence for one ingredient does not automatically prove that a three-ingredient product works. The formula, dose, population, comparison group, and outcome all matter. A 2012 Cochrane review found no eligible randomized, placebo-controlled trials of huperzine A for mild cognitive impairment.
It concluded that the evidence was insufficient to assess the ingredient's potential and called for larger, rigorous trials. The regulatory history also deserves context. In a 2015 stipulated federal order, the FTC barred named defendants from making certain cognition or memory-loss claims about covered products without qualifying human clinical evidence. The defendants neither admitted nor denied the complaint's allegations.
What safety questions should readers ask?
The FDA says it has not evaluated vinpocetine's effectiveness for marketed uses such as memory and focus. It also tentatively concluded in 2016 that vinpocetine might not qualify as a lawful dietary-supplement ingredient.
Most importantly, the FDA warns that vinpocetine may cause miscarriage or harm fetal development. Pregnant people and those who could become pregnant should not take products containing it. Before using Procera AVH:.
- Show the complete label to a clinician or pharmacist, along with all medicines and supplements.
- Ask how the undisclosed ingredient doses affect the safety review.
- Mention anticoagulant use because the cited trial excluded those users.
- Do not use the supplement as a test of whether memory symptoms are serious.
- Ask the manufacturer whether the current formula matches the exact doses studied in 2019.
